-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604.P1.61 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 1, 2018: 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)

Anetta Marcinek, MSc1,2*, Bettina Brauchle, MSc1,2*, Dragica Udiljak1,2*, Roman Kischel, MD3*, Peter Kufer, MD3*, Karsten Spiekermann, MD2,4,5, Michael von Bergwelt, MD2*, Felix S. Lichtenegger, MD1,2* and Marion Subklewe, MD5,6,7*

1Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany
2Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
3Amgen Research (Munich) GmbH, Munich, Germany
4Experimental Leukemia and Lymphoma Research (ELLF) Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany
5German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
6Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, University of Munich, Munich, Germany
7Translational Cancer Immunology, Gene Center, University of Munich, Munich, Germany

Samir H Barghout, BSPharm, MSc1,2, Neil MacLean1*, G. Wei Xu1*, Geethu Thomas, PhD, MSc, BSc1, Zachary Blatman1,3*, Rose Hurren, BSc1* and Aaron D Schimmer, MD, PhD2,4

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
3Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
4Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

Christopher Peter Mill, PhD, BA1*, Tianyu Cai, PhD2*, Warren Fiskus, BSc, PhD3, Gautam Borthakur, MD4, Steven M. Kornblau, MD5, Tapan M. Kadia, MD6, Courtney D. DiNardo, MD, MSc7, Agnieszka J Nowak1*, Dyana T. Saenz, PhD1, David N Saenz1*, Baohua Sun, MD, PhD8*, Thurika Ganesh9*, Wendy Jin10*, Vaishnavi Rao10*, Joseph David Khoury, MD11, Yu Shen12*, Marina Y. Konopleva, MD, PhD4 and Kapil N. Bhalla, MD4

1MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
3Leukemia, The Methodist Hospital Research Institute, Houston, TX
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
7University of Texas MD Anderson Cancer Center, Houston, TX
8M.D. Anderson Cancer Ctr., Houston, TX
9Leukemia, MD Anderson Cancer Center, Houston
10MD Anderson Cancer Center, Houston
11Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
12AbbVie Inc., North Chicago, IL

Lauren Forbes, BS, MS1,2*, Krasnopolsky Isaac, BA1*, Gerard Minuesa Dinares, PhD1*, Michael G. Kharas, PhD1 and Alex Kentsis, MD, PhD1

1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY

Xiaofei He, B.S.1*, Mark Wunderlich, MS2*, Benjamin Mizukawa, MD2, James C. Mulloy, PhD3, Saran Feng, M.D., Ph.D.1,4*, Lauren Lawley, B.S.1*, Caleb Hawkins, B.S.1*, Wenxin Fan, B.S.1*, Guokun Zhou, Ph.D.5*, Xiang-ming Zha, Ph.D.5*, Jiajia Zhang, PhD6*, Johnie Hodge, M.D., Ph.D.7*, Daping Fan, Ph.D.7*, Stephanie Halene, MD 8 and Jing Fang, MD, PhD1

1Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC
2Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
4Department of Hematology, Shandong Provincial Qianfoshan Hospital, Jinan, China
5Department of Physiology and Cell Biology, University of South Alabama College of Medicine, Mobile, AL
6University of South Carolina Arnold School of Public Health, Columbia
7Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC
8Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale Univ. School of Medicine, New Haven, CT

Lei Guo, PhD*, Jia Li, PhD*, Shaohai Fang, MS*, Minjung Lee, MS*, Hongxiang Zeng, PhD, Tingting Li, MD*, Wei Han, MS*, Deqiang Sun, PhD* and Yun Huang, PhD

Center for Epigenetics and Disease Prevention, Texas A&M University, Institute of Biosciences and Technology, Houston, TX

Timothy S. Pardee, MD, PhD1,2, Scott Isom, M.S.3*, Leslie Renee Ellis, MD, MSHPEd4, Dianna S. Howard, MD5, Rupali Bhave, M.D.3*, Megan Manuel, M.S.N3*, Sarah Dralle, M.S.N.3*, Susan Lyerly, P.A.-C.3* and Bayard L. Powell, MD3

1Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC
2Rafael Pharmaceuticals, Newark, NJ
3Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC
4Wake Forest University School of Medicine, Winston Salem, NC
5Wake Forest Baptist Health, Winston-Salem, NC

Anup Kumar Singh, MS, PhD1 and Xiaochun Yu, MD, PhD2*

1Beckman Research Institute, City of Hope, Duarte, CA
2Department of Cancer Genetics and Epigenetics, Beckman Research Institute at City of Hope, Duarte, CA

John Roboz1*, Shyamala C. Navada, MD2, Sool Yeon Cho, PhD2*, Michael E. Petrone, MD, MPH3, Steven M. Fruchtman, MD 4 and Lewis R. Silverman, MD5

1Icahn School of Medicine at Mount Sinai, Bronx, New York
2Icahn School of Medicine at Mount Sinai, New York, NY
3Onconova Therapeutics, Newtown, PA
4Onconova Therapeutics, Inc., Newtown, PA
5Icahn School of Medicine at Mount Sinai, Sleepy Hollow, NY

Shaowei Qiu, MD1,2*, Andrew J Paterson, PhD1*, Ajay Abraham, PhD1, Jianbo He, MD1, Mansi Shah, PhD1, Puneet Agarwal, PhD1*, Amanda K Mullen1*, Hui Li, BS1*, Mason W Harris1*, Nicholas R Anderson1* and Ravi Bhatia, MD1

1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL
2Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Ruth Meier1*, Gabriele Greve2*, Christoph Niemöller1*, Heiko Becker1, Tobias Ma1*, Ralitsa Langova3*, Björn Grüning4*, Lars Feuerbach3*, Daniel B. Lipka5*, Justus Duyster, Prof.6*, Benedikt Brors3*, Christoph Plass5* and Michael Lübbert1

1Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany
2Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
3Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany
4Bioinformatics Group, Department of Computer Science, University of Freiburg, Freiburg, Germany
5Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany
6Department of Hematology, Oncology, and Stem-Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany

Jieun Jang, MD1*, Ju-In Eom2*, Hoi-kyung Jeung2*, So-Young Seol2*, Haerim Chung, M.D.1*, Yu Ri Kim, MD3, June-Won Cheong, MD, PhD1 and Yoo Hong Min, MD, PhD1

1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
2Avison Biomedical Research Center, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
3Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Daniel A Luedtke, BS1, Yongwei Su2*, Holly Edwards, BS3*, Lisa Polin, PhD3*, Juiwanna Kushner3*, Sijana H Dzinic, PhD3*, Hai Lin, MD4*, Jeffrey W. Taub, MD5 and Yubin Ge, PhD3

1Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI
2Jilin University, Changchun, China
3Oncology, Wayne State University School of Medicine, Detroit, MI
4Department of Hematology and Oncology, The First Hospital of Jilin University, Changchun, China
5Department of Pediatrics, Wayne State University School of Medicine, Detroit

David J Young, MD, PhD1,2, Jun O Liu, PhD1,3* and Donald Small, MD, PhD1,2

1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
2Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
3Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

Mathias A. Schneeweiss1,2*, Gabriele Stefanzl1,2*, Daniela Berger1*, Gregor Eisenwort1,2*, Mohamad Jawhar3*, Greiner Georg, MD, PhD4*, Gregor Hoermann2,4,5, Wolfgang R. Sperr1,2*, Michel Arock6*, Andreas Reiter, MD7*, Peter Valent1,2 and Karoline V. Gleixner, MD1,2*

1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
2Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
3Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany
4Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
5MLL Munich Leukemia Laboratory, Munich, Germany
6CNRS UMR8113, Ecole Normale Supérieure de Paris-Saclay, Cachan, France
7Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany

Roya Rafiee, PhD1,2, Soheil Meshinchi, MD, PhD3 and Jatinder K Lamba, PhD4

1University of Florida, Gainesville
2University of Florida, Gainesville, FL
3Fred Hutchinson Cancer Research Center, Seattle, WA
4Department of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Pharmacotherapy and Translational Re, Gainesville, FL

Mara Rosenberg, BS1, Cristina E. Tognon, PhD2,3*, Kevin M Watanabe-Smith, Ph.D.4 and Uma Borate, MD2

1OHSU, Portland, OR
2Knight Cancer Institute, Oregon Health & Science University, Portland, OR
3Knight Cancer Institute, OHSU, Portland, OR
4Oregon Health and Science University, Portland, OR

*signifies non-member of ASH